

CITATION REPORT

List of articles citing

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

DOI: 10.7326/0003-4819-111-8-641

Annals of Internal Medicine, 1989, 111, 641-9.

Source: <https://exaly.com/paper-pdf/21017884/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
614	Safety of azathioprine in pregnancy in inflammatory bowel disease. 1990 , 99, 443-6		228
613	Inflammatory bowel disease revisited: newer drugs. 1990 , 175, 97-106		12
612	Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. 1990 , 336, 16-9		263
611	Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. 1990 , 336, 526-9		200
610	Initial clinical experience with dideoxynucleosides as single agents and in combination therapy. 1990 , 616, 328-43		38
609	Azathioprine in the treatment of children with inflammatory bowel disease. 1990 , 117, 809-14		108
608	Inflammatory bowel disease. Part II: Clinical and therapeutic aspects. 1991 , 37, 669-746		16
607	6-mercaptopurine therapy in selected cases of corticosteroid-dependent Crohn's disease. 1991 , 66, 480-4		21
606	Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. 1991 , 6, 192-219		61
605	The use of 6-mercaptopurine in adolescents with Crohn's disease. 1991 , 101, 1459		3
604	Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. 1991 , 101, 39-46		162
603	Reply. 1991 , 101, 1459		
602	Kaposi's sarcoma of the colon in a young HIV-negative woman with Crohn's disease. 1991 , 36, 528-31		13
601	Inflammatory bowel disease (2). 1991 , 325, 1008-16		276
600	Mercaptopurine-induced fever in a patient with Crohn's disease. 1992 , 26, 907-9		3
599	Medical therapy in Crohn's disease. 1992 , 92, 169-73, 177-8, 183 passim		2
598	New therapeutic agents in the treatment of inflammatory bowel disease. 1992 , 93, 199-208		25

597	Medical management of severe inflammatory disease of the rectum and distal colon: non-nutritional aspects. 1992 , 6, 1-26	4
596	Effect of oral cyclosporin on renal function in Crohn's disease. 1993 , 38, 1624-30	12
595	Treatment of Crohn's disease recurrence after ileoanal anastomosis by azathioprine. 1993 , 38, 1558-60	19
594	Current management of inflammatory bowel disease. 1993 , 8, 70-83	10
593	Maintenance of symptomatic remission in patients with Crohn's disease. 1993 , 68, 1183-90	14
592	Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. 1993 , 34, 1081-5	355
591	Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. 1993 , 105, 367-72	189
590	Inflammatory bowel disease. 1993 , 40, 1213-31	3
589	Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. 1994 , 330, 1846-51	222
588	Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease. 1994 , 331, 883-4	91
587	Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity. 1994 , 39, 1638-41	31
586	Immunomodulator therapy in inflammatory bowel disease. 1994 , 39, 1885-92	38
585	Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. 1994 , 343, 1249-52	414
584	Hepatotoxicity of 6-mercaptopurine and azathioprine. 1994 , 69, 498	4
583	[Treatment of Crohn disease in adults]. 1994 , 15, 676-89	
582	Hepatotoxicity of 6-Mercaptopurine and Azathioprine: The authors reply. 1994 , 69, 498	2
581	Inflammatory Bowel Disease. 1994 , 2, 134-160	5
580	Medical therapy of inflammatory bowel disease. 1994 , 78, 1413-26	18

579	Characterization of Hepatic Abnormalities in Children with Inflammatory Bowel Disease. 1995 , 1, 27-33	23
578	Do Immunosuppressives Cause Cancer in IBD Patients?. 1995 , 1, 166-167	1
577	Effects of immunosuppressive drugs during pregnancy. 1995 , 38, 1722-32	101
576	Characterization of hepatic abnormalities in children with inflammatory bowel disease. 1995 , 1, 27-33	16
575	Inflammatory bowel disease: a retrospective review of a specialist-based cohort. 1995 , 163, 133-6	15
574	A controlled double blind study of azathioprine in the management of Crohn's disease. 1995 , 37, 674-8	433
573	The management of ulcerative colitis. 1995 , 46, 497-505	15
572	Methotrexate for Crohn's disease. 1995 , 333, 600-1	10
571	Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. 1995 , 332, 292-7	782
570	The prevention of Crohn's disease after surgery: metronidazole is a small but continuous medical advancement. 1995 , 108, 1935-8	7
569	European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group. 1995 , 109, 774-82	130
568	An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. 1995 , 109, 1808-17	132
567	Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. 1995 , 39, 456-9	160
566	Ulcerative colitis in children. 1996 , 43, 235-54	21
565	Newer treatments for inflammatory bowel disease. 1996 , 23, 577-608	10
564	Inflammatory bowel disease. 1996 , 334, 841-8	365
563	6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. 1996 , 39, 401-6	257
562	Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. 1996 , 347, 215-9	381

561	Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy. 1996 , 74, 580-585	55
560	Safety of Drug Therapy for Inflammatory Bowel Disease in Pregnant and Nursing Women. 1996 , 2, 33-47	11
559	Clinical Trials in IBD: A Pediatric Perspective. 1996 , 2, 118-120	
558	Postpartum avulsion of the terminal ileal wall in Crohn's disease. 1996 , 66, 849-51	3
557	Safety of drug therapy for inflammatory bowel disease in pregnant and nursing women. 1996 , 2, 33-47	14
556	Clinical trials in IBD: A pediatric perspective. 1996 , 2, 118-120	
555	Review article: the medical management of Crohn's disease. 1996 , 10, 1-22	34
554	Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. 1996 , 39, 63-8	77
553	A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. 1997 , 37, 38-46	17
552	Immunosuppressive drug use during pregnancy. 1997 , 23, 149-67	78
551	Primary intestinal Hodgkin's disease complicating ileal Crohn's disease. 1997 , 67, 485-9	21
550	Safety of corticosteroids and immunosuppressive agents in ulcerative colitis. 1997 , 11, 111-28	2
549	Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. 1997 , 62, 464-75	132
548	Acute myeloblastic leukemia following prolonged treatment of Crohn's disease with 6-mercaptopurine. 1998 , 43, 1791-3	17
547	Crohn's disease in adolescents. 1998 , 12, 115-32	6
546	Consensus conference on the evaluation of drugs to treat children with inflammatory bowel disease. Philadelphia, Pennsylvania, USA. October 18-19, 1997. 1998 , 4, 101-31	2
545	Lipophilic drug derivatives in liposomes. 1998 , 165, 129-168	171
544	Advances in the management of Crohn's disease: economic and clinical potential of infliximab. 1998 , 20, 1009-28	46

543	Methotrexate in patients with Crohn's disease after 6-mercaptopurine. 1998 , 132, 830-5	73
542	Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. 1998 , 115, 813-21	191
541	Gastrointestinal diseases in women. 1998 , 82, 21-50	12
540	Novel approaches to inflammatory bowel disease. 1998 , 7, 1099-113	1
539	6-Mercaptopurine hepatotoxicity during acute lymphocytic leukemia maintenance therapy. 1998 , 4, 117-120	
538	Azathioprine in inflammatory bowel disease, a safe alternative?. 1998 , 7, 141-4	17
537	Renal and urologic complications of inflammatory bowel disease. 1998 , 93, 504-14	93
536	Inflammatory bowel diseases: a new wave of therapy. 1998 , 8, 785-818	2
535	Azathioprine for maintaining remission of Crohn's disease. 2000 , CD000067	78
534	Which immunosuppressors do you use to treat Crohn's disease and ulcerative colitis? In which order of priority and how worried are you about toxicity?. 1998 , 4, 248-52; discussion 253-4	3
533	Toxicity of 6-mercaptopurine/azathioprine in patients with inflammatory bowel disease. 1998 , 4, 116-7	17
532	Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. 2000 , CD000545	68
531	Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. 1999 , 44, 625-8	178
530	Anti-TNF antibody treatment of Crohn's disease. 1999 , 58 Suppl 1, I114-20	21
529	Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease. 1999 , 94, 424-6	37
528	Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. 1999 , 94, 3248-53	97
527	A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. 1999 , 13, 1597-604	66
526	Ileocaecal Epstein-Barr virus-positive lymphoproliferative disorder complicating Crohn's disease. 1999 , 35, 388-90	19

525	Inflammatory bowel disease. 1999 , 26, 141-70	14
524	The relationship between infliximab treatment and lymphoma in Crohn's disease. 1999 , 117, 1433-7	167
523	Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. 1999 , 117, 527-35	195
522	Medical therapy for inflammatory bowel disease. 1999 , 28, 297-321	66
521	Cancer risk in patients with inflammatory bowel disease. 1999 , 28, 459-77, x	104
520	Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy. 1999 , 21, 311-23	57
519	The therapeutic potential of PDE4 inhibitors. 1999 , 8, 1301-25	35
518	Immunosuppressors for inflammatory bowel disease: how long is long enough?. 2000 , 6, 251-7; discussion 158	10
517	Prediction of treatment refractoriness in ulcerative colitis and Crohn's disease--do we have reliable markers?. 2000 , 6, 123-31	17
516	How to do without steroids in inflammatory bowel disease. 2000 , 6, 48-57; discussion 58	67
515	Update in medical treatment of Crohn's disease. 2000 , 31, 282-91	12
514	Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. 2000 , 6, 16-20	37
513	Therapy for Crohn disease. 2000 , 16, 318-23	6
512	The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. 2000 , 14, 1561-5	49
511	Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. 2000 , 45, 1810-3	48
510	Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. 2000 , 45, 1601-7	7
509	The pancreas and inflammatory bowel diseases. 2000 , 27, 171-9	27
508	Intravenous azathioprine in severe ulcerative colitis: a pilot study. 2000 , 95, 3463-8	26

507	Risk of lymphoma in inflammatory bowel disease. 2000 , 95, 2308-12	135
506	Prevention of pancreatitis by weekly amylase assay in patients with Crohn's disease treated with azathioprine. 2000 , 95, 2394-5	8
505	Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. 2000 , 47, 514-9	183
504	A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. 2000 , 342, 1627-32	593
503	Chronic inflammatory bowel disease and pregnancy. 2000 , 35, 673-8	2
502	Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. 2000 , 95, 684-8	126
501	Tratamiento médico de la enfermedad de crohn. 2000 , 8, 279-283	
500	Advances in inflammatory bowel disease. 2000 , 84, 1107-24	5
499	Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits?. 2000 , 32, 518-31	25
498	Hepatitis related to cytomegalovirus infection in two patients with Crohn's disease treated with azathioprine. 2000 , 32, 626-9	10
497	A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. 2000 , 119, 895-902	662
496	Comparative tolerability of treatments for inflammatory bowel disease. 2000 , 23, 429-48	135
495	Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. 2000 , 118, 705-13	844
494	Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. 2000 , 118, 1018-24	203
493	Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. 2000 , 118, 1025-30	493
492	Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine. 2001 , 120, 1483-4	125
491	Inflammatory bowel disease is not associated with an increased risk of lymphoma. 2001 , 121, 1080-7	259
490	Lymphoma risk in inflammatory bowel disease: influences of referral bias and therapy. 2001 , 121, 1239-42	23

489	Pharmacokinetic considerations in the treatment of inflammatory bowel disease. 2001 , 40, 723-51	97
488	Use of azathioprine or 6-mercaptopurine for treatment of steroid-dependent lymphocytic and collagenous colitis. 2001 , 96, 2798-9	42
487	Linfoma ki-1 cutáneo en paciente con enfermedad de crohn en tratamiento con azatioprina. 2001 , 24, 271-272	1
486	Acute and chronic pancreatitis. 2001 , 28, 607-28, vii	9
485	[Fulminant infection caused by varicella herpes zoster in patient with Crohn disease undergoing treatment with azathioprine]. 2001 , 24, 47	15
484	Inflammatory bowel disease in the elderly. 2001 , 30, 409-26	57
483	Medical therapy for Crohn's disease: the state of the art. 2001 , 81, 71-101, viii	23
482	Hepatotoxicity of chemotherapy. 2001 , 6, 162-76	323
481	Azathioprine for prevention of postoperative recurrence in Crohn's disease: a retrospective study. 2001 , 13, 1291-6	28
480	Rectal lymphoma in ulcerative colitis treated with azathioprine. 2001 , 13, 989-92	10
479	Safety and efficacy of azathioprine in the maintenance of ciclosporin-induced remission of ulcerative colitis. 2001 , 15, 1307-11	31
478	Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. 2001 , 15, 1101-8	50
477	Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. 2001 , 15, 1699-708	149
476	Review article: does the use of immunosuppressive therapy in inflammatory bowel disease increase the risk of developing lymphoma?. 2001 , 15, 1843-9	29
475	Cancer risk in patients with inflammatory bowel disease: a population-based study. 2001 , 91, 854-62	932
474	Conventional treatment of Crohn's disease: objectives and outcomes. 2001 , 7 Suppl 1, S2-8	19
473	The incidence of lymphoid and myeloid malignancies among hospitalized Crohn's disease patients. 2001 , 7, 106-12	38
472	Inflammatory bowel disease and pregnancy. 2001 , 7, 146-57	43

471	An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. 2001 , 7, 181-9	103
470	Drugs in pregnancy. Gastrointestinal disease. 2001 , 15, 937-52	16
469	Management and outcome of pregnancy in autoimmune hepatitis. 2001 , 48, 97-102	170
468	Neutropenia is not required for clinical remission during azathioprine therapy in inflammatory bowel disease. 2001 , 13, 1053-5	8
467	Infliximab treatment for Crohn's disease. 2001 , 77, 436-40	17
466	Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. 2001 , 48, 642-6	240
465	Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. 2001 , 49, 656-64	149
464	Novel therapies in the treatment of ulcerative colitis. 2001 , 10, 1223-9	1
463	Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990-2000. 2002 , 97, 928-32	23
462	The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. 2002 , 50, 485-9	439
461	Methotrexate for induction of remission in refractory Crohn's disease. 2003 , CD003459	11
460	Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. 2002 , 12, 429-36	198
459	Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease. 2002 , 35, 240-4	50
458	Severe pancytopenia from thiopurine methyltransferase deficiency: a preventable complication of 6-mercaptopurine therapy in children with Crohn disease. 2002 , 35, 695-9	3
457	Corticosteroid-sparing treatments in patients with Crohn's disease. 2002 , 97, 1607-17	21
456	Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. 2002 , 122, 72-7	217
455	6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. 2002 , 122, 904-15	427
454	Comparative tolerability of therapies for ulcerative colitis. 2002 , 25, 561-82	22

453	Medical therapy for ulcerative colitis. 2002 , 31, 147-66	34
452	Colonic dysplasia and cancer in inflammatory bowel disease. 2002 , 12, 495-523	25
451	[Individualized therapy with azathioprine or 6-mercaptopurine by monitoring thiopurine methyl-transferase (TPMT) activity]. 2002 , 202, 555-62	13
450	Inflammatory bowel disease in the pediatric and adolescent patient. 2002 , 31, 275-91	17
449	[Questions and answers on the role of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease]. 2002 , 25, 401-15	21
448	Recent developments in inflammatory bowel disease. 2002 , 86, 1497-523	13
447	[Indications for azathioprine treatment in inflammatory bowel disease]. 2002 , 25, 319-26	0
446	Medical management of inflammatory bowel disease in the new millennium. 2002 , 28, 39-49	1
445	Review article: the management of refractory Crohn's disease. 2002 , 16 Suppl 4, 40-7	16
444	Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. 2002 , 16, 79-85	89
443	Review article: Immunosuppressants in distal ulcerative colitis. 2002 , 16, 181-7	12
442	Review article: monitoring for drug side-effects in inflammatory bowel disease. 2002 , 16, 647-62	58
441	Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease?. 2002 , 16, 857-67	53
440	Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. 2002 , 16, 1225-32	140
439	Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. 2002 , 16, 1743-50	180
438	Teratogen update: azathioprine and 6-mercaptopurine. 2002 , 65, 240-61	163
437	Optimizing immunomodulator therapy for inflammatory bowel disease. 2003 , 5, 506-11	27
436	6-thioguanine: a new old drug to procure remission in inflammatory bowel disease. 2003 , 33, 44-6	11

435	6-thioguanine--efficacy and safety in chronic active Crohn's disease. 2003 , 17, 503-8	52
434	Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. 2003 , 17, 827-34	117
433	Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. 2003 , 18, 401-8	56
432	Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. 2003 , 18, 395-400	72
431	Treatment of inflammatory bowel disease in childhood: best available evidence. 2003 , 9, 34-58	88
430	Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. 2003 , 9, 237-45	46
429	[Thiopurine methyltransferase activity and myelosuppression in inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine]. 2003 , 121, 1-5	5
428	Inflammatory bowel disease in pregnancy. 2003 , 32, 323-40	35
427	Cáncer de cólix invasivo en paciente en tratamiento crónico con 6-mercaptopurina por enfermedad de crohn. 2003 , 26, 52-53	
426	[Opportunistic infections in patients with inflammatory bowel disease undergoing immunosuppressive therapy]. 2003 , 26, 19-22	17
425	AGA technical review on perianal Crohn's disease. 2003 , 125, 1508-30	468
424	Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. 2003 , 125, 320-7	252
423	6-mercaptopurine beats a bum rap. 2003 , 125, 610-2	2
422	Is there any remaining role for methotrexate for Crohn's disease?. 2003 , 35, 610-1	3
421	Optimizing treatment with thioguanine derivatives in inflammatory bowel disease. 2003 , 17, 37-46	21
420	The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. 2003 , 124, 9-17	268
419	Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. 2003 , 47, 1-10	28
418	Novel therapies in the treatment of ulcerative colitis. 2003 , 12, 483-90	4

417	The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration. 2003 , 3, 291-301	26
416	Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. 2003 , 98, 2372-82	81
415	The effects of infliximab maintenance therapy on health-related quality of life. 2003 , 98, 2232-8	94
414	6-TG for IBD. simple, but safe?. 2003 , 98, 950-2	1
413	Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. 2003 , 98, 1058-63	83
412	6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. 2003 , 15, 63-7	60
411	Optimizing the therapeutic potential of azathioprine/6-mercaptopurine in the treatment of inflammatory bowel disease. 2003 , 36, 379-81	8
410	Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting. 2003 , 36, 390-5	26
409	Primary intestinal lymphoma complicating Crohn's disease. 2003 , 36, 332-6	14
408	Acute pancreatitis after long-term therapy with mesalazine, and hyperamylasaemia associated with azathioprine in a patient with ulcerative colitis. 2003 , 15, 933-4	17
407	Complications of pregnancy and child development after cessation of treatment with 6-mercaptopurine for inflammatory bowel disease. 2003 , 36, 303-9	27
406	Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease. 2003 , 36, 234-7	23
405	Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. 2003 , 37, 220-5	68
404	Diagnosis and Treatment of Inflammatory Bowel Disease. 2003 , 46, 605	
403	Systemic consequences of intestinal inflammation. 2003 , 235-250	1
402	Medical treatment of ulcerative colitis. 2004 , 17, 7-19	37
401	A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. 2004 , 99, 1122-8	97
400	A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. 2004 , 99, 462-5	25

399	Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. 2004 , 99, 1371-85	514
398	The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. 2004 , 99, 1744-8	81
397	Mycophenolate mofetil for Crohn's disease: short-term efficacy and long-term outcome. 2004 , 19, 427-34	29
396	Review article: The medical treatment of Crohn's perianal fistulas. 2004 , 19, 953-67	46
395	Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year. 2004 , 19, 1147-52	47
394	Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis. 2004 , 20, 161-6	38
393	Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. 2004 , 20, 593-9	113
392	Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. 2004 , 20, 843-50	73
391	Epstein-Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy. 2004 , 10, 85-90	53
390	Pharmacogenetics and inflammatory bowel disease: progress and prospects. 2004 , 10, 148-58	12
389	Epstein-Barr virus-associated lymphoma in Crohn's disease. 2004 , 10, 425-9	32
388	Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease. 2004 , 10, 657-60	63
387	Hypersensitivity reaction to azathioprine in a patient with ulcerative colitis. Infrequent manifestations. 2004 , 10, 700	10
386	CDP571, a humanized anti-tumor necrosis factor-alpha monoclonal antibody in pediatric Crohn's disease. 2004 , 10, 723-30	16
385	Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. 2004 , 23, 306-9	69
384	Choosing Therapy on the Basis of Disease Classifications in Inflammatory Bowel Disease. 2004 , 7, 169-179	
383	Pharmacogenetics of inflammatory bowel disease. 2004 , 18, 597-609	1
382	Methotrexate for induction of remission in refractory Crohn's disease. 2005 , CD003459	53

381	Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. 2004 , 33, 209-34, viii	46
380	Treatment of fistulizing Crohn's disease. 2004 , 33, 421-54, xi-xii	32
379	Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. 2004 , 2, 731-43	171
378	Methotrexate in inflammatory bowel disease. 2004 , 33, 407-20, xi	20
377	Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. 2004 , 127, 723-9	385
376	Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy. 2004 , 24, 479-86	25
375	Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients. 2004 , 16, 705-10	18
374	Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis. 2004 , 16, 1407-13	33
373	Side effects of azathioprine in patients with Crohn's disease. 2004 , 16, 207-12	46
372	MEAN CORPUSCULAR VOLUME: A SIMPLE AND INEXPENSIVE WAY TO MONITOR AZATHIOPRINE/6-MERCAPTOPURINE TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE?. 2004 , 5, 22-23	
371	[A systematic review of the clinical effectiveness of azathioprine in patients with ulcerative colitis]. 2004 , 124, 555-60	9
370	Drug-induced pancreatitis: an update. 2005 , 39, 709-16	266
369	CAN WE RESET THE IMMUNOSTAT? A RANDOMIZED, DOUBLE-BLIND, CONTROLLED WITHDRAWAL TRIAL IN CROHN'S DISEASE PATIENTS WIN LONG-TERM REMISSION TAKING AZATHIOPRINE. 2005 , 6, 114-115	
368	The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. 2005 , 56, 169-78	43
367	A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. 2005 , 21, 373-84	31
366	Review article: monitoring of immunomodulators in inflammatory bowel disease. 2005 , 21, 307-19	55
365	Review article: practical management of inflammatory bowel disease patients taking immunomodulators. 2005 , 22, 1-16	88
364	Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. 2005 , 22, 775-82	91

363	Mesenteric pulsatility index analysis predicts response to azathioprine in patients with Crohn's disease. 2005 , 11, 126-32	16
362	Use of 6-mercaptopurine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: con. 2005 , 11, 200-2	0
361	Crohn's jejunoileitis: the pediatrician's perspective on diagnosis and management. 2005 , 11, 696-704	21
360	Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes. 2005 , 11, 1080-4	45
359	Immunomodulators and the need for surgery in Crohn's disease: insufficient evidence to convict. 2005 , 11, 1120-2	
358	RBC 6-TGN and hematological parameters in patients with Crohn's disease treated by azathioprine. 2005 , 29, 1264-9	19
357	Development of hepatocellular carcinoma following treatment with 6-mercaptopurine for ulcerative colitis: investigation of chromosomal aberration by comparative genomic hybridization. 2005 , 10, 281-4	2
356	Colonic gastrointestinal autonomic nervous tumor in a patient with Crohn's disease. 2005 , 50, 1476-80	3
355	On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients. 2005 , 11, 5540-4	36
354	Medical management of ulcerative colitis. 2003 , 605-629	
353	Clinical pharmacology in inflammatory bowel disease: optimizing current medical therapy. 2003 , 495-521	1
352	Incidence of adverse reactions to azathioprine in patients with Crohn's disease. 2005 , 2, 510-1	1
351	Drug safety in the treatment of Crohn's disease. 2005 , 71, 8-12	4
350	Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. 2005 , 51, 2282-8	74
349	The use of medications for inflammatory bowel disease during pregnancy and nursing. 2005 , 6, 1833-9	9
348	Genetic testing in Crohn disease: utility in individualizing patient management. 2005 , 5, 213-22	10
347	A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. 2005 , 43, 303-9	78
346	Biologic therapy for inflammatory bowel disease. 2005 , 65, 2253-86	199

345	A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. 2005 , 128, 1812-8	279
344	Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. 2006 , 4, 621-30	724
343	Infliximab in fistulizing Crohn's disease. 2006 , 35, 795-820	21
342	Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. 2006 , 4, 1483-90	145
341	Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. 2006 , 24, 767-81	66
340	Current therapy of inflammatory bowel disease in children. 2006 , 8, 279-302	79
339	Therapy insight: drugs for gastrointestinal disorders in pregnant women. 2006 , 3, 256-66	16
338	Induction by activated macrophage-like THP-1 cells of apoptotic and necrotic cell death in intestinal epithelial Caco-2 monolayers via tumor necrosis factor-alpha. 2006 , 312, 3909-19	73
337	Cancer in Crohn's disease. 2006 , 35, 621-39	41
336	American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. 2006 , 130, 940-87	351
335	Biological therapy in the management of recent-onset Crohn's disease: why, when and how?. 2006 , 66, 1431-9	27
334	[Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease]. 2006 , 29, 568-83	15
333	Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. 2006 , 4, 44-9	127
332	Clinical outcome of Crohn's disease according to the Vienna classification: disease location is a useful predictor of disease course. 2006 , 18, 255-61	42
331	Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease. 2006 , 28, 45-50	40
330	Predictors of immunomodulator use as early therapy in pediatric Crohn's disease. 2006 , 40, 145-8	37
329	Pharmacogenetics of thiopurine therapy in paediatric IBD patients. 2006 , 23, 1137-41	32
328	Review article: thiopurines in inflammatory bowel disease. 2006 , 24, 715-29	120

327	Review article: Medical therapy for fistulizing Crohn's disease. 2006 , 24, 1283-93	36
326	Systematic review: managing anaemia in Crohn's disease. 2006 , 24, 1507-23	216
325	Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: A Danish nationwide cohort study. 2007 , 25, 73-81	79
324	Reactive hemophagocytic syndrome complicating the treatment of inflammatory bowel disease. 2006 , 12, 573-80	34
323	Thiopurines in inflammatory bowel disease: new strategies for optimization of pharmacotherapy?. 2006 , 8, 89-92	5
322	Hepatotoxicity of chemotherapy. 2006 , 33, 50-67	176
321	Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. 2006 , 93, 793-9	75
320	Ulcerative colitis: diagnosis and management. 2006 , 333, 340-3	43
319	Typing TPMT and ITPase to detect azathioprine toxicity. 2006 , 3, 45-59	5
318	Bullous pemphigoid treatment review. 2006 , 7, 2403-11	6
317	Drug therapy of inflammatory bowel disease in fertile women. 2006 , 101, S633-9	8
316	Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. 2006 , 101, 2769-76	88
315	Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte/monocyte apheresis. 2007 , 23, 2715-28	13
314	Low-dose naltrexone therapy improves active Crohn's disease. 2007 , 102, 820-8	87
313	Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. 2007 , 4, 686-94	88
312	Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. 2007 , 102, 2488-94	79
311	Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease. 2007 , 42, 194-9	14
310	Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. 2007 , 41, 21-8	70

309	Drug safety in Crohn's disease therapy. 2007 , 76, 161-8	15
308	Treatment response and colonic gene expression in patients with Crohn's disease. 2007 , 42, 834-40	8
307	Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. 2007 , 41, 682-8	44
306	Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. 2007 , CD000478	82
305	Inflammatory bowel disease: clinical aspects and established and evolving therapies. 2007 , 369, 1641-57	1301
304	Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. 2007 , 102, 2737-46	40
303	The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. 2007 , 102, 794-802	139
302	Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. 2007 , 46, 187-208	118
301	Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. 2007 , 102, 1518-27	153
300	Current medical therapy for chronic inflammatory bowel diseases. 2007 , 87, 697-725	15
299	[Common errors in the management of the seriously ill patient with inflammatory bowel disease]. 2007 , 30, 294-314	0
298	The long-term efficacy of azathioprine does not wane after four years of continuous treatment in patients with steroid-dependent luminal Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2007 , 1, 28-34	1.5 10
297	Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?. 2007 , 39, 156-9	35
296	Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. 2007 , 13, 1106-14	88
295	Controversies in Pediatric Inflammatory Bowel Disease. 2007 , 4, 203-227	5
294	Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study. 2007 , 22, 268-74	29
293	A triangulation study of the clinician and patient experiences of the use of the immunosuppressant drugs azathioprine and 6-mercaptopurine for the management of inflammatory bowel disease. 2007 , 16, 1427-34	4
292	Review article: immunosuppressive therapy for inflammatory bowel disease. 1993 , 7, 117-23	14

291	Rolling review: inflammatory bowel disease. 1993 , 7, 567-79	17
290	Review article: the risks of malignancy from either immunosuppression or diagnostic radiation in inflammatory bowel disease. 1995 , 9, 465-70	16
289	Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. 2007 , 25, 1069-77	82
288	Meta-analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. 2007 , 26, 643-52	60
287	Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. 2007 , 26, 987-1003	78
286	[Primary CNS lymphoma in azathioprine therapy for autoimmune diseases: review of the literature and case report]. 2007 , 78, 451-6	2
285	Review article: multiple myeloma and inflammatory bowel disease. 2007 , 52, 2022-8	13
284	Clinical pharmacology and pharmacogenetics of thiopurines. 2008 , 64, 753-67	287
283	Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger. 2008 , 14, 750-5	34
282	In the case of nonresponse, what is the second-level treatment for induction of remission in Crohn's disease?. 2008 , 14 Suppl 2, S251-2	
281	Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. 2008 , 28, 623-8	95
280	Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a case-control study. 2008 , 28, 606-13	19
279	Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. 2008 , 28, 734-41	102
278	Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. 2008 , 28, 973-83	124
277	The haemotoxicity of azathioprine in repeat dose studies in the female CD-1 mouse. 2008 , 89, 138-58	10
276	Drug-induced pancreatitis : incidence, management and prevention. 2008 , 31, 823-37	123
275	[Infectious mononucleosis in patients with inflammatory bowel disease under treatment with azathioprine]. 2008 , 31, 289-92	5
274	Lower doses of 6-mercaptopurine/azathioprine bring enough clinical efficacy and therapeutic concentration of erythrocyte 6-mercaptopurine metabolite in Japanese IBD patients. <i>Journal of Crohn's and Colitis</i> , 2008 , 2, 315-21	1.5 22

273	The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. 2008 , 40, 814-20	35
272	Infections and IBD. 2008 , 5, 18-27	64
271	Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. 2008 , 103, 1783-800	180
270	Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications. 2008 , 2, 23-34	13
269	Immunosuppressant medications and mortality in inflammatory bowel disease. 2008 , 103, 1428-35; quiz 1436	84
268	Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol. 2008 , 7, 607-16	28
267	Ethnic variation of thiopurine S-methyltransferase activity: a large, prospective population study. 2008 , 9, 303-9	35
266	Specific considerations in the treatment of pediatric inflammatory bowel disease. 2008 , 2, 105-24	9
265	In the case of nonresponse, what is the second-level treatment for induction of remission in Crohn's disease?. 2008 , 14, S251-S252	
264	Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease. 2008 , 47, 123-9	13
263	Health care expenditures in ulcerative colitis: the perspective of a self-insured employer. 2008 , 50, 969-77	16
262	Paradoxical elevated thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age. 2008 , 30, 390-3	15
261	The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. 2009 , 2, 101-9	52
260	Inflammatory bowel disease and pregnancy: evidence, uncertainty and patient decision-making. 2009 , 23, 49-53	11
259	Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. 2009 , 104, 2760-7	90
258	Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. 2009 , 27, 5972-8	269
257	[Azathioprine metabolism: what to do or not to do in clinical practice?]. 2009 , 33, 172-5	
256	Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. 2009 , 29, 1106-13	64

255	Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. 2009 , 17, 991-8	36
254	Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat. 1995 , 10, 132-8	67
253	L-cysteine supplementation attenuates local inflammation and restores gut homeostasis in a porcine model of colitis. 2009 , 1790, 1161-9	86
252	[Immunosuppressed woman with fever, dyspnea and pulmonary infiltrates]. 2009 , 132, 638-44	
251	[Optimising azathioprine treatment: determination of thiopurine methyltransferase activity and thiopurine metabolites]. 2009 , 70, 126-31	1
250	Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations. 2009 , 7, 1195-201; quiz 1141-2	45
249	High frequency of parasitic and viral stool pathogens in patients with active ulcerative colitis: report from a tropical country. 2009 , 44, 325-31	26
248	Safety profile of IBD therapeutics: infectious risks. 2009 , 38, 691-709	32
247	Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. 2009 , 7, 80-5	126
246	Safety profile of IBD: lymphoma risks. 2009 , 38, 669-89	11
245	Severe myelosuppression following alopecia shortly after the initiation of 6-mercaptopurine in a patient with Crohn's disease. 2009 , 48, 693-5	8
244	Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. 2009 , CD000545	27
243	Lésions crohniennes de l'anus et du pŕinŕ. 2010 , 5, 1-12	
242	Allopurinol salvage therapy in pediatric overlap autoimmune hepatitis-primary sclerosing cholangitis with 6-MMP toxicity. 2010 , 51, 524-6	6
241	Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. 2010 , 50 Suppl 1, S1-13	108
240	Pancreatitis in inflammatory bowel diseases. 2010 , 44, 246-53	65
239	Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. 2010 , 188, 125-32	35
238	New pathophysiological insights and modern treatment of IBD. 2010 , 45, 571-83	144

237	The genetics of inflammatory bowel disease: diagnostic and therapeutic implications. 2010 , 6, 203-9	8
236	Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. 2010 , 16, 881-95	100
235	Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. 2010 , 16, 1598-619	146
234	Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy. 2010 , 16, 2168-72	21
233	Early years of biological agents therapy in Crohn's disease and risk of the human polyomavirus JC reactivation. 2010 , 224, 316-26	15
232	l-Tryptophan exhibits therapeutic function in a porcine model of dextran sodium sulfate (DSS)-induced colitis. 2010 , 21, 468-75	132
231	Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease. 2010 , 31, 120-4	14
230	Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. 2010 , 31, 640-7	120
229	Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies. 2010 , 3, 15-31	7
228	The long-term risk of continuous immunosuppression using thioguanides in inflammatory bowel disease. 2010 , 1, 7-16	18
227	Thiopurine therapy in inflammatory bowel disease. 2010 , 4, 575-88	17
226	Amino acid-responsive Crohn's disease: a case study. 2010 , 3, 171-7	18
225	Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. 2010 , 6, 621-31	31
224	Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases. 2010 , 29, 4-37	9
223	Bone marrow suppression in the setting of normal thiopurine methyltransferase phenotype testing. 2010 , 49, 901-3	1
222	Lymphoma with central nervous system involvement in a young patient with Crohn disease treated with azathioprine. 2010 , 51, 790-2	2
221	Thiopurines in Crohn's disease, is there something new?. 2010 , 6, 1505-14	7
220	Efficacy and safety of drugs for ulcerative colitis. 2010 , 9, 573-92	24

219	Pulmonary diseases associated with inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2010 , 4, 384-9	1.5	24
218	Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. 2010 , 105, 501-23; quiz 524		917
217	[Pulmonary manifestations associated with immunosuppressive treatments used in transplantation and autoimmune diseases]. 2010 , 39, 878-86		
216	Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. 2010 , CD000545		64
215	Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. 2010 , 42, 97-114		200
214	Safety profile of IBD therapeutics: infectious risks. 2010 , 94, 115-33		16
213	Patients with late-adult-onset ulcerative colitis have better outcomes than those with early onset disease. 2010 , 8, 682-687.e1		57
212	Safety profile of IBD: lymphoma risks. 2010 , 94, 93-113		2
211	Change in hematologic indices over time in pediatric inflammatory bowel disease treated with azathioprine. 2010 , 10, 213-7		8
210	Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical use and efficacy. <i>Journal of Crohn's and Colitis</i> , 2011 , 5, 397-401	1.5	21
209	Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease. 2011 , 34, 385-92		22
208	Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. 2011 , 34, 306-17		33
207	Azathioprine in ulcerative colitis: Why, when, how and how long to use it. 2011 , 72, 733-738		2
206	Response to Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. <i>Inflamm Bowel Dis</i> 2011 [Epub ahead of print]. 2011 , 17, E161-2; author reply E163		
205	Lymphoma in inflammatory bowel disease and treatment decisions. 2012 , 107, 964-70		14
204	Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. 2012 , CD000478		69
203	Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. 2012 , 57, 2408-15		109
202	Strategies for the care of adults hospitalized for active ulcerative colitis. 2012 , 10, 1315-1325.e4		46

201	[Guidelines for the management of ulcerative colitis]. 2012 , 59, 118-40			25
200	[Guidelines for the management of Crohn's disease]. 2012 , 59, 141-79			16
199	Varicella zoster virus infection in inflammatory bowel disease. 2012 , 18, 2392-403			74
198	Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. 2012 , 35, 15-36			118
197	Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single-centre experience. 2012 , 35, 284-91			16
196	Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. 2013 , 19, 15-22			162
195	Recent advances using immunomodulators for inflammatory bowel disease. 2013 , 53, 575-88			30
194	Chemotherapy-induced hepatotoxicity. 2013 , 17, 671-86, ix-x			28
193	"In vitro" azathioprine-induced changes in peripheral T cell apoptosis and IFN- γ production associate with drug response in patients with Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2013 , 7, 441-50	1.5		10
192	Reassessing the risks and benefits of thiopurines in Crohn's disease. 2013 , 11, 395-7			
191	Usefulness of thiopurine metabolites in predicting azathioprine resistance in pediatric IBD patients. 2013 , 53, 900-8			8
190	Mercaptopurine-induced hepatoportal sclerosis in a patient with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2013 , 7, 590-3	1.5		10
189	Efficacy, safety and tolerability of vedolizumab in patients with inflammatory bowel disease: the ENTRANCE study. <i>Journal of Crohn's and Colitis</i> , 2013 , 7, 636-43	1.5		45
188	Medical Treatment of Perianal Crohn Disease Fistulae. 2013 , 385-397			
187	Cancer Chemotherapy. 2013 , 541-567			5
186	Practical guidelines for the use of steroid-sparing agents in the treatment of chronic pruritus. 2013 , 26, 120-34			6
185	Patent portfolios for biotech inventions. 2013 , 31, 501-3			3
184	Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. 2013 , 145, 766-74.e1			180

183	Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. 2013 , CD000545	54
182	Do inflammatory bowel disease therapies cause cancer?. 2013 , 19, 1306-21	42
181	The influence of CTGF single-nucleotide polymorphisms on outcomes in Crohn's disease. 2013 , 258, 767-73; discussion 773-4	7
180	The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. 2013 , 33, 1-8	43
179	[Is there any interest to dose the azathioprine's metabolites during inflammatory bowel diseases?]. 2013 , 68, 313-20	1
178	Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. 2013 , 19, 1404-10	190
177	Management of the elderly patients with inflammatory bowel disease: practical considerations. 2013 , 19, 2257-72	17
176	The effect of NOD2 polymorphism on postsurgical recurrence in Crohn's disease: a systematic review and meta-analysis of available literature. 2013 , 19, 1099-105	20
175	Role of thiopurine metabolite testing and thiopurine methyltransferase determination in pediatric IBD. 2013 , 56, 333-40	30
174	[How should azathioprine be dosed in Crohn's disease? a novel strategy of maximum dose-titration based on the lower limit of leukocyte count and tolerability]. 2013 , 62, 111-6	0
173	[A case of pleomorphic liposarcoma in a patient with Crohn's disease taking azathioprine]. 2013 , 62, 248-52	0
172	Use of thiopurines in inflammatory bowel disease. 2013 , 19, 1040-8	26
171	[Determining the dose of azathioprine based on the lower limit of leukocyte count in patients with Crohn's disease]. 2013 , 62, 83-4	
170	Pulmonary manifestations of inflammatory bowel disease. 2014 , 20, 13501-11	49
169	Hepatotoxicity Secondary to Chemotherapy. 2014 , 2, 95-102	71
168	Differences in the adverse effects of azathioprine between inflammatory bowel disease and autoimmune hepatitis in Korean patients. 2014 , 64, 348-55	2
167	Monitoring thiopurine metabolites in Korean pediatric patients with inflammatory bowel disease. 2014 , 55, 1289-96	8
166	Update on the Treatment of Intestinal Behçet's Disease. 2014 , 21, 176	

165	Pulmonary manifestations of Crohn's disease. 2014 , 20, 133-41	31
164	6-Mercaptopurine reduces macrophage activation and gut epithelium proliferation through inhibition of GTPase Rac1. 2014 , 20, 1487-95	31
163	Hepatobiliary manifestations of inflammatory bowel disease. 2014 , 20, 1655-67	17
162	The application of RNAi-based treatments for inflammatory bowel disease. 2014 , 4, 4-18	9
161	A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. 2014 , 46, 1017-20	321
160	Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. 2014 , 8, 223-40	60
159	Curcumin and inflammatory bowel disease: potential and limits of innovative treatments. 2014 , 19, 21127-53	80
158	Cancer and immunomodulators in inflammatory bowel diseases. 2015 , 21, 674-98	37
157	Impact of drug therapy and surgery on quality of life in Crohn's disease: a systematic review. 2015 , 21, 1187-94	55
156	Early Thiopurines Versus Conventional Step-Care Therapy for Modifying the Disease Course of Early Crohn's Disease: A Tertiary Referral Center Cohort Study. 2015 , 94, e1148	6
155	Safety Profile of Thiopurines in Crohn Disease: Analysis of 893 Patient-Years Follow-Up in a Southern China Cohort. 2015 , 94, e1513	24
154	New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us?. 2015 , 21, 2948-57	1
153	A nurse-driven outpatient clinic for thiopurine-treated inflammatory bowel disease patients reduces physician visits and increases follow-up efficiency. 2015 , 38, 116-20	4
152	Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseases. 2015 , 47, 281-90	19
151	Medical Therapy for Crohn's Disease: The Present. 2015 , 35-48	
150	A practical guide to the use of thiopurines in oral medicine. 2015 , 44, 761-8	9
149	Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance. 2015 , 60, 195-204	22
148	What Is the Best Therapy for My Moderate to Severe Ulcerative Colitis? State-of-the-Art Therapy for Moderate to Severe Ulcerative Colitis. 2015 , 79-89	

147	Synthesis of novel thiopurine pyranonucleosides: evaluation of their bioactivity. 2015 , 34, 289-308		3
146	Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases. 2015 , 41, 1141-8		27
145	Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's disease. 2015 , 60, 1414-23		24
144	The role and advances of immunomodulator therapy for inflammatory bowel disease. 2015 , 9, 177-89		22
143	Mercaptopurine and inflammatory bowel disease: the other thiopurine. 2017 , 109, 10-16		5
142	Elderly patients and inflammatory bowel disease. 2016 , 7, 51-65		36
141	Thiopurines in the Management of Crohn's Disease: Safety and Efficacy Profile in Patients with Normal TPMT Activity-A Retrospective Study. 2016 , 2016, 1034834		12
140	The Evolving Role of Thiopurines for Inflammatory Bowel Disease. 2016 , 22, 234-40		7
139	Designer Thiopurine-analogues for Optimised Immunosuppression in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 1132-43	1.5	13
138	Standard-dose versus low-dose azathioprine in the treatment of Crohn's disease: A prospective randomized study. 2016 , 17, 747-755		3
137	Review article: acute severe ulcerative colitis - evidence-based consensus statements. 2016 , 44, 127-44		53
136	Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. 2016 , 10, CD000545		33
135	Azathioprine and mercaptopurine. 2016 , 759-781		
134	Management and Prevention of Herpes Zoster in the Immunocompromised Inflammatory Bowel Disease Patient: A Clinical Quandary. 2016 , 22, 2538-47		14
133	Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. 2016 , CD000478		73
132	Influences of XDH genotype by gene-gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn's disease. 2016 , 51, 684-91		6
131	EPA- and DHA-derived resolvins' actions in inflammatory bowel disease. 2016 , 785, 156-164		54
130	Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches. <i>Handbook of Experimental Pharmacology</i> , 2017 , 239, 115-146	3.2	41

129 Thiopurines in Crohn's Disease. **2017**, 321-331

128 The need for better preventative strategies for inflammatory bowel disease patients at risk of herpes zoster virus. **2017**, 47, 1263-1269

2

127 Pharmacology of Thiopurine Therapy in Inflammatory Bowel Disease and Complete Blood Cell Count Outcomes: A 5-Year Database Study. **2017**, 39, 399-405

14

126 Management and Prevention of Infectious Diseases in IBD Patients. **2017**, 621-638

125 More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing. **2017**, 23, 1873-1881

15

124 The Liver in Oncology. **2017**, 21, 697-707

4

123 Therapeutic Drug Monitoring in Inflammatory Bowel Disease: History and Future Directions. **2017**, 64, 1309-1326

7

122 Second Korean guidelines for the management of ulcerative colitis. **2017**, 15, 7-37

40

121 [Second Korean Guideline for the Management of Ulcerative Colitis]. **2017**, 69, 1-28

16

120 HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease. **2018**, 47, 615-620

37

119 Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients. **2018**, 19, 31-43

25

118 Curcumin as a therapeutic agent for blocking NF- κ B activation in ulcerative colitis. **2018**, 40, 476-482

37

117 Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients. **2019**, 55,

7

116 Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics. **2019**, 64, 2395-2403

11

115 Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment. **2019**, 50, 407-415

12

114 Dietary Support in Elderly Patients with Inflammatory Bowel Disease. **2019**, 11,

6

113 Therapy for Crohn's Disease. **2019**, 150-172

112 genotyping in Caucasian patients can help to optimise thiopurine treatment in patients with inflammatory bowel disease. **2019**, 4, 81

2

111 Medikament  induzierte akute Pankreatitis. **2019**, 17, 101-107

110 Genotype-based Treatment With Thiopurine Reduces Incidence of Myelosuppression in Patients With Inflammatory Bowel Diseases. **2020**, 18, 2010-2018.e2

17

109 How to manage IBD in the 'elderly'. **2020**, 11, 468-477

5

108 NUDT15 genotyping during azathioprine treatment in patients with inflammatory bowel disease: implications for a dose-optimization strategy. **2020**, 8, 437-444

3

107 Infecciones y esclerosis sist mica: un desaf o emergente. **2020**, 27, 62-84

106 Infections and systemic sclerosis: an emerging challenge. **2020**, 27, 62-84

1

105 Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis. **2020**, 51, 1286-1304

4

104 Analysis of Gene Signatures of Tumor Microenvironment Yields Insight Into Mechanisms of Resistance to Immunotherapy. **2020**, 8, 348

2

103 Influence of TPMT polymorphisms on azathioprine-induced myelosuppression in Bangladeshi patients with systemic lupus erythematosus. **2020**, 36, 202-207

4

102 Pancreatitis associated with azathioprine and 6-mercaptopurine use in Crohn's disease: a systematic review.. **2021**, 12, 423-436

1

101 Apprehending Ulcerative Colitis Management With Springing Up Therapeutic Approaches: Can Nanotechnology Play a Nascent Role?. **2021**, 9, 9-32

1

100 Real-World Long-Term Remission Maintenance for 10 Years With Thiopurines in Ulcerative Colitis. **2021**, 3,

99 Informed consent in inflammatory bowel disease: a necessity in real-world clinical practice. **2021**, 34, 466-475

98 Multifocal colorectal non-Hodgkin's lymphoma in a patient with ulcerative colitis: A case report. **2021**, 64, S92-S94

1

97 Polyphenols from food by-products: An alternative or complementary therapy to IBD conventional treatments. **2021**, 140, 110018

9

96 Systematic review and meta-analysis of drug induced liver injury secondary to biologic medications in inflammatory bowel disease. **2021**, 5, 005-012

0

95 Pretreatment HLA-DQA1-HLA-DQB1 Testing for the Prevention of Azathioprine-Induced Pancreatitis in Inflammatory Bowel Disease: A Prospective Cohort Study. **2021**, 12, e00332

0

94 How to do without steroids in inflammatory bowel disease. 6, 48-57

19

93	Prediction of treatment refractoriness in ulcerative colitis and Crohn's disease-do we have reliable markers?. 6, 123-131	4
92	Drosophila as a Tool for Investigating the Molecular Genetics of Insecticide Resistance. 1993 , 1-37	4
91	Pregnancy and Myasthenia Gravis. 2002 , 28-39	2
90	Crohn's Disease. 2010 , 1941-1973.e9	4
89	Ulcerative Colitis. 2010 , 1975-2013.e9	2
88	THE ROLE OF THE MUCOSAL IMMUNE SYSTEM IN INFLAMMATORY BOWEL DISEASE. 1992 , 21, 451-502	78
87	CONVENTIONAL DRUG THERAPY IN INFLAMMATORY BOWEL DISEASE. 1995 , 24, 509-521	12
86	HEPATOTOXICITY OF CHEMOTHERAPEUTIC AND ONCOLOGIC AGENTS. 1995 , 24, 969-990	44
85	ULCERATIVE COLITIS AND CROHN'S DISEASE IN CHILDREN: Diagnosis and Management. 1995 , 24, 99-117	12
84	5-Aminosalicylic acid, 1,000-mg caplets versus 500-mg tablets, in maintenance of remission in ulcerative colitis. 1997 , 24, 287-8	7
83	Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. 1997 , 25, 330-3	79
82	Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease. 1999 , 28, 341-4	42
81	Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn's disease in children. 2000 , 30, 294-8	54
80	Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. 2000 , 30, 409-13	39
79	Disseminated nocardiosis complicating medical therapy in Crohn's disease. 1997 , 25, 233-5	10
78	Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. 1999 , 28, 54-8	52
77	Drug management of ulcerative colitis. 1992 , 305, 35-8	5
76	Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk. 2011 , 3, RRN1236	46

75	Nephrolithiasis as a common urinary system manifestation of inflammatory bowel diseases; a clinical review and meta-analysis. 2017 , 6, 264-269	10
74	Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. 2008 , 14, 5512-8	32
73	Pharmacogenetics in inflammatory bowel disease. 2006 , 12, 3657-67	37
72	Long term results of use of azathioprine in patients with ulcerative colitis in India. 2006 , 12, 7332-6	22
71	Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease. 2012 , 18, 197-204	30
70	Thiopurines in inflammatory bowel disease revisited. 2013 , 19, 1699-706	39
69	Expert opinion: experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. 2013 , 19, 2979-84	13
68	Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective. 2016 , 22, 10103-10117	29
67	Influence of variants on hematological pictures of patients with inflammatory bowel disease treated with thiopurines. 2018 , 24, 511-518	8
66	Guidelines for the Management of Ulcerative Colitis. 2012 , 10, 1	9
65	Guidelines for the Management of Crohn's Disease. 2012 , 10, 26	9
64	Frequency of Bone Marrow Toxicity by Using Pattern of Azathioprine in Inflammatory Bowel Disease Patients. 2012 , 10, 244	1
63	Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID). 2015 , 13, 193-207	42
62	Bakterien und Viren bei chronisch-entzündlichen Darmerkrankungen. 2001 , 71-83	
61	Konservative Therapie der Fistelerkrankung beim Morbus Crohn. 2001 , 71-80	
60	Clinical pharmacology in inflammatory bowel disease: optimizing current medical therapy. 2003 , 495-521	1
59	Medical management of ulcerative colitis. 2003 , 605-629	
58	Systemic consequences of intestinal inflammation. 2003 , 235-250	

- 57 MEDICAL TREATMENT OF ULCERATIVE COLITIS AND OTHER COLITIDES. **2005**, 203-210
- 56 Azathioprine: long-term side-effects. **2006**, 142-151
- 55 Azathioprine and mercaptopurine. **2006**, 377-387
- 54 Medical Therapy of Fistulizing Crohn's Disease. **2006**, 171-179
- 53 Drug Therapy of Inflammatory Bowel Disease in Fertile Women. **2006**, 101, S633-S639 o
- 52 Treatment of Perianal Crohn Disease Fistulae. **2008**, 429-446
- 51 CROHN'S DISEASE: AETIOLOGY, PATHOLOGY, DIAGNOSIS AND MEDICAL TREATMENT. **2008**, 1783-1862
- 50 INFLAMMATION AND IMMUNOMODULATION. **2009**, 157-172
- 49 IMMUNE MODULATORS. **2010**, 491-598
- 48 GLUCOCORTICOIDS AND DISEASE MODIFYING ANTIRHEUMATIC DRUGS. **2010**, 371-667
- 47 Crohn's Disease. **2010**, 211-231
- 46 Hepatic and Gastrointestinal Disease. **2011**, 839-860.e4
- 45 Inflammatory bowel disease. **2011**, 86-92
- 44 Management and Prevention of Infectious Diseases in Inflammatory Bowel Disease Patients. **2012**, 679-700
- 43 Liver Disease in Pediatric Inflammatory Bowel Disease. **2013**, 95-107 1
- 42 6-Mercaptopurine Therapy. **2013**, 331-337
- 41 Management of Steroid-Dependent and Steroid-Refractory Ulcerative Colitis. **2014**, 313-320
- 40 Azathioprine/6-Mercaptopurine Metabolism in Ulcerative Colitis: A Guide to Metabolite Assessment—An Evidence-Based Approach. **2014**, 145-151

- 39 Safety Considerations in the Medical Therapy of Ulcerative Colitis. **2014**, 297-311
- 38 Principles of Medical Management of Ulcerative Colitis. **2014**, 31-44
- 37 Immunosuppressive Drugs: Do They Have Any Role in the Treatment of IBD?. **1990**, 227-234
- 36 Unusual Skin Lesions in a Patient with Diarrhea. **1991**, 198-212
- 35 Drug-Induced Pancreatitis. **1993**, 169-186
- 34 Medikamente und ihre Wirkungsweisen. **1993**, 161-183
- 33 Immunosuppressive agents in IBD: current status and future prospects. **1994**, 367-373
- 32 A gastroenterologist's perspective of the medical management of patients with Crohn's disease and ulcerative colitis. **1994**, 385-423
- 31 Preventing relapse after surgery for Crohn's disease: where do we go from here?. **1997**, 25, 114-5 2
- 30 Entzündliche Erkrankungen des Dickdarms, Anorektums und Perianalbereichs. **1998**, 337-405
- 29 6-Mercaptopurine in chronic ulcerative colitis: two steps forward with another step back?. **1999**, 28, 17-8
- 28 Medical Therapy. **1999**, 138-149 1
- 27 Ulcerative Colitis. 1378-1417
- 26 Medical Treatment of Perianal Crohn's Disease Fistulae. **2017**, 451-464
- 25 6-Mercaptopurine Therapy. **2017**, 375-381
- 24 Infectious Complications of Pediatric Inflammatory Bowel Disease. **2017**, 605-614
- 23 NUDT15 genetic testing-guided 6-mercaptopurine dosing in children with ALL likely to be cost-saving in China. **2021**, 1 0
- 22 Extraintestinale Manifestationen chronisch entzündlicher Darmerkrankungen. **2020**, 49, 530-537

21	Analysis of genetic signatures of tumor microenvironment yields insight into mechanisms of resistance to immunotherapy.		
20	Pancreatic exocrine insufficiency and Crohn's disease. 2020 , 66, 17-22		0
19	The first-principles study of BC3 nanosheet as the delivery vehicle for 6-mercaptopurine drug.		2
18	Pharmacogenetics of inflammatory bowel disease therapy. 24-33		
17	Follow-Up of Restorative Proctocolectomy: Clinical Experience of a Specialised Pouch Clinic. 2006 , 293-300		
16	6-Mercaptopurine Therapy. 2008 , 371-378		
15	Inflammatory Bowel Disease in Pregnancy. 2008 , 593-609		
14	Increased risk of morbidity associated with immunomodulatory treatment in patients with inflammatory bowel diseases. 85-98		
13	IBD and Pregnancy. <i>MedGenMed: Medscape General Medicine</i> , 2004 , 6, 14		6
12	Herpes simplex virus encephalitis during immunosuppressive treatment of ulcerative colitis. <i>MedGenMed: Medscape General Medicine</i> , 2004 , 6, 7		5
11	Biologic targeting in the treatment of inflammatory bowel diseases. <i>Biologics: Targets and Therapy</i> , 2009 , 3, 77-97	4.4	84
10	Refractory ulcerative colitis treatment. <i>Gastroenterology and Hepatology</i> , 2007 , 3, 64-9	0.7	4
9	A Physician's Guide to Azathioprine Metabolite Testing. <i>Gastroenterology and Hepatology</i> , 2006 , 2, 58-63	0.7	4
8	Adverse Effects of Immunosuppression: Infections. <i>Handbook of Experimental Pharmacology</i> , 2021 ,	3.2	
7	The thiopurine tale: an unexpected journey.. <i>Journal of Crohn's and Colitis</i> , 2022 ,	1.5	0
6	Data_Sheet_1.docx. 2020 ,		
5	Presentation_1.zip. 2020 ,		
4	Medical Treatment of Perianal Crohn Disease. 2023 , 495-509		0

- 3 6-Mercaptopurine-induced fever in a case of B-acute lymphoblastic leukemia: A case report. **2022**, 5, 788 ○
- 2 Metal-decorated E-graphyne as a drug transporting agent for the mercaptopurine chemotherapy drug: a DFT study. **2023**, 25, 9461-9471 ○
- 1 Infectious Complications of Pediatric Inflammatory Bowel Disease. **2023**, 687-697 ○